Article Information
History
- October 7, 2016.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Matthew J. Maurer1,
- Lawrence Sutardja2,
- Dominic Pinel1,
- Stefan Bauer1,3,
- Amanda L. Muehlbauer1,
- Tyler D. Ames1,4,
- Jeffrey M. Skerker1,2,5,* and
- Adam P. Arkin1,2,6,**
- 1Energy Biosciences Institute, University of California, Berkeley, California, United States of America.
- 2Department of Bioengineering, University of California, Berkeley, California, United States of America.
- 3Present address: Zymergen, Emeryville, California, United States of America.
- 4Present address: Phosplatin Therapeutics, New York, New York, United States of America.
- 5Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, California, United States of America.
- 6Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, California, United States of America.